Jazz Pharmaceuticals Plc Receives Consensus Rating of “Buy” from Brokerages (NASDAQ:JAZZ)
Shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) have been given a consensus rating of “Buy” by the eighteen analysts that are presently covering the company, Stock Ratings Network reports. Three investment analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $118.71.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals Plc in a research note to investors on Friday, January 24th. They now have a $167.00 price target on the stock. Finally, analysts at UBS AG raised their price target on shares of Jazz Pharmaceuticals Plc from $130.00 to $164.00 in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded down 0.61% on Monday, hitting $152.16. 264,540 shares of the company’s stock traded hands. Jazz Pharmaceuticals Plc has a one year low of $50.76 and a one year high of $159.14. The stock’s 50-day moving average is $140.8 and its 200-day moving average is $104.1. The company has a market cap of $8.793 billion and a P/E ratio of 26.02.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.